Clinical Trial Update: Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating mesenchymal stem cells for efficacy and safety in patients with respiratory distress from COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Mesenchymal Stem Cells (MSC) (mesenchymal stem cells)

Snippet

Sponsor: Banc de Sang i Teixits | Conditions: COVID-19, SARS-CoV 2 | Phase 1, Phase 2 | Status: COMPLETED